Camden-based Coriell Institute for Medical Research has named Jean-Pierre Issa its new CEO and president, effective Feb. 28, it announced Thursday.
“Dr. Issa brings to Coriell a life’s worth of scientific vision and inspired leadership in the academic and clinical setting,” Kiep said. “His guidance will bolster the Institute’s global reputation in increasingly vital scientific areas such as cancer epigenetics and the translation of that work into new therapies,” Robert Kiep III, Coriell’s board of trustees chairman, said.
Prior to Coriell, Issa was the director at Temple University’s Fels Institute for Cancer Research and Molecular Biology, deputy director of the Fox Chase Cancer Center (part of the Temple University Health System) and co-leader of Temple’s department of cancer epigenetics. He’s also been a professor of medicine in the Lewis Katz School of Medicine at Temple University.
“Dr. Issa brings to Coriell a life’s worth of scientific vision and inspired leadership in the academic and clinical setting,” Kiep said. “His guidance will bolster the Institute’s global reputation in increasingly vital scientific areas such as cancer epigenetics and the translation of that work into new therapies.”
“The Coriell Institute for Medical Research is a very unique organization in the world of biomedical research – one that has rich history, yet is also always looking at the horizon,” Issa said. “I’m eager to lead this group and to continue that legacy. The institute is internationally recognized for its personalized medicine research and the quality of its biobanking and I look forward to the opportunity to expand the institute’s offerings and capabilities.”
Before joining Temple in 2011, Issa was the chief of translational research in the Department of Leukemia at the University of Texas M.D. Anderson Cencer.
